Form 4: Ionis Pharma Exec Exercises Options, Sells Shares

Ionis Pharmaceuticals' EVP, Chief Human Resources Officer, Shannon L. Devers, exercised stock options and subsequently sold a portion of her common stock holdings.

Summary

• Shannon L. Devers, EVP, Chief Human Resources Officer of Ionis Pharmaceuticals Inc. (IONS), reported transactions on November 25, 2025.
• Devers acquired 16,777 shares of common stock by exercising non-qualified stock options at a price of $53.77 per share.
• Immediately following the acquisition, Devers sold 16,777 shares of common stock at a weighted average price of $80.9109 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on September 3, 2024.
• The shares were sold in multiple transactions with prices ranging from $80.66 to $81.14.
• Following these transactions, Devers' direct beneficial ownership of common stock is 17,494 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine insider transaction involving the exercise of options and subsequent sale of shares, often for liquidity or tax purposes, and was conducted under a pre-arranged 10b5-1 trading plan. It does not reflect a change in company fundamentals or a strong positive/negative signal.

Positives

• The exercise of stock options indicates that the company's stock price was above the option's strike price, allowing the executive to realize value.
• The executive realized a profit of approximately $27.14 per share on the exercised and sold shares ($80.9109 sale price $53.77 exercise price).

Negatives

• The sale of shares by an insider reduces their direct beneficial ownership in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a routine insider transaction filing (Form 4) and does not provide information directly related to broader industry trends or competitive landscape. Such transactions are common for executives managing their equity compensation.

Stakeholder Impact

• Shareholders: The transaction represents a minor reduction in direct insider ownership, which is generally not considered significant given the pre-planned nature of the sale. It also demonstrates an executive realizing value from their equity compensation.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Insider Trading, Form 4, Stock Options, Rule 10b5-1, Executive Compensation, Share Sale